Abu Dhabi, United Arab Emirates - Today, 10X Health (USA) and REVIV Global (UK) announced a strategic partnership with M42 , a global leader in health technology, artificial intelligence and genomics, headquartered in Abu Dhabi, to launch 10XREVIV , marking a pioneering collaboration that will facilitate access to a unique micronutrient system in the Middle East.

10XREVIV represents a new paradigm shift in personalized health improvement, combining genomics, blood biomarker analysis, and nutritional intelligence using the company’s proprietary AI technologies to deliver accurate and personalized health solutions for each individual.

The 10X Micronutrient System forms the core of this innovation. It is a patented life sciences platform developed by the 10X Health biotechnology team over more than a decade. The system analyzes up to 20 million genetic variants with an accuracy of up to 99.97%, combining this data with blood and lifestyle indicators to produce a comprehensive and secure health report of over 400 pages.

Based on these findings, the system offers targeted, scientifically supported health solutions and guidance, including:

• 10X Micro Supplements are genetically engineered microgranular formulations designed to ensure optimal absorption of over 22 micronutrients.
• The 10X precise weight management program, where carbohydrates and fats are customized according to each individual's metabolic indicators and genes.
• Microintravenous therapy, which consists of patented global intravenous injection protocols, is designed according to each individual’s genetic information and provides personalized intravenous micronutrient nutrition through accredited and trusted medical facilities.

In addition to launching the system, this partnership will also establish a leading micro-care clinic focused on life extension, conduct a randomized controlled trial to evaluate the impact of parenteral nutrition on type 2 diabetes, and provide a micro-nutrition training curriculum to educate physicians on how to translate genetic insights into clinical practices that contribute to improved health outcomes and longer healthy lifespan.

Brandon Dawson , co-founder, chairman and CEO of 10X Health , stated: "Our mission at 10X Health is to revolutionize the way people understand and improve their body biology. The partnership between M42 and REVIV Global enables us to combine proprietary AI technologies, genomics, and clinical excellence to deliver customized solutions that will fundamentally change people's lives, all at the heart of a region that is leading the future of healthcare."

Albarah El Khani , Chief Operating Officer of M42’s integrated healthcare solutions platform, added: “This collaboration embodies M42’s vision of using advanced science and technology to enhance people’s health so they can enjoy health and wellness for longer. By leveraging 10XREVIV , we are integrating genetics, blood biomarkers, and micronutrient systems into the daily care model, making Abu Dhabi a model that will lay the foundation for the future of life-extending medicine.”

Sarah Lomas , CEO and founder of REVIV Global , stated: "The collaboration with 10X Health and M42 enables us to take the lead in a new era of precision health and longevity. I would like to point out that the 10XREVIV initiative is the culmination of years of clinical experience and technological innovation, combining artificial intelligence, genetics, and practical application to empower individuals and drive modern wellness globally."

10X Health , REVIV Global and M42 are coming together under one collaborative umbrella, combining biotechnology innovation mechanisms, deep clinical expertise and AI-powered data science to set new global standards in precision health.

The 10X Micronutrient Systems powered by M42 set standards that contribute to improving human health and extending lifespan globally.

About 10X Health

10X Health is a US-based biotechnology and wellness company focused on employing genetics and artificial intelligence to improve human performance, health, and longevity. The patented 10X Precision System integrates genetic, biochemical, and clinical data to deliver personalized nutritional and therapeutic solutions for each individual.

For more information, please visit www.10xhealthsystem.com .

About REVIV Global

REVIV Global is a leading UK-based life sciences and wellness company specializing in clinically advanced intravenous therapies, genetic testing, and precision nutrition. Operating in over 40 countries, REVIV has successfully delivered more than 3 million intravenous treatments globally, setting a benchmark for safe and effective personalized wellness care.

For more information, please visit www.revivme.com .

About the M42

M42 is a global healthcare company that leverages artificial intelligence, technology, and genomics to drive innovation in healthcare for the benefit of people and the planet. Headquartered in Abu Dhabi, M42 combines state-of-the-art facilities and integrated healthcare solutions, such as genomics and biobanks, to deliver precise, preventative, and predictive care. Its goal is to transform traditional healthcare models and create a positive, long-lasting impact on people's lives worldwide.

M42 , established in 2023 following the merger of G42 Healthcare and Mubadala Health , has over 480 facilities in 26 countries and more than 20,000 employees. Its portfolio includes prominent healthcare providers such as Cleveland Clinic Abu Dhabi , Danat Al Emarat , Diaverum , Imperial College London Diabetes Centre , Sheikh Sultan bin Zayed Hospital , and Moorfields Eye Hospital Abu Dhabi . In addition to managing the UAE Genome Programme, M42 also operates Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS) , a global technology-driven healthcare company that manages the Malaffi platform.

For more information, please visit https://m42.ae/ .

Contacts

For press and media inquiries related to 10X Health , please contact Media@10Xhealthsystem.com

For press and media inquiries related to REVIV , please contact Press@revivme.com

-I finish-

#Company Data

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.